Meet the Compound: Laquinimod – HD Insights
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Teva drops development of laquinimod - PharmaTimes
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
laquinimod
Roquinimex - wikidoc
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
Patient enrollment in Phase III trial of laquinimod completed
AhR activators - friend or foe? - Hypha Discovery Blogs
A Broad Look At Teva's Pipeline (NYSE:TEVA) | Seeking Alpha
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Laquinimod | 99.96%(HPLC) | In Stock | Immunology & Inflammation related modulator
PDF) Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva hit with largest-ever fine under US anti-corruption act - PMLiVE
Molecules | Free Full-Text | Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
Laquinimod | C19H17ClN2O3 | CID 54677946 - PubChem
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
